Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. (NASDAQ:AZN) to develop ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to delay its full-year 2025 results, according to ...

British pharma major AstraZeneca (LSE: AZN) is expanding its oncology-focused artificial intelligence collaboration with US ...

CEE banks navigated war, taxes, and lower rates through consolidation, digital innovation and aggressive regional expansion strategies.

UK dividends rose by more than a fifth in the first quarter to £16.4 billion kicking off a strong start to the year for income investors, despite short-term uncertainty caused by the conflict in the ...

Today promises to be very important for the entire tech sector. Why? Shares of Cerebras will begin trading on the Nasdaq ...

Fasenra (benralizumab) has received US Food and Drug Administration (FDA) approval for the treatment of patients 12 years and older with hypereosinophilic syndrome (HES) without an identifiable ...

Use our currency converter to find the live exchange rate between AZN and PLN. Convert Azerbaijani Manat to Polish Zloty ...

Use our currency converter to find the live exchange rate between AZN and EUR. Convert Azerbaijani Manat to Euro ...

An independent advisory committee of the U.S. Food and Drug Administration has recommended the use of AstraZeneca’s (AZN) anti-tumor agent Truqap (capivasertib) as part of a combination regimen for a ...

AstraZeneca (AZN) announced on Monday another late-stage trial win for its antibody therapy, tozorakimab, which is targeted at patients with chronic obstructive pulmonary disease, a respiratory ...

Looking ahead to 2030, our model projects AZN could trade at an average price of $292.67, with a potential range between $219.50 and $365.84. This represents a potential 58.2% return from today's ...